[Abstract] Heparan sulfate (HS) is purified from complex matrices and often not fully characterised to validate its assignment. The characterisation of heparins and heparan sulfates through enzymatic depolymerisation and subsequent strong anion-exchange high performance liquid chromatography (SAX-HPLC) analysis and quantitation of the resulting disaccharides is a critical tool for assessing the structural composition of this class of compound. This protocol details a methodology to reproducibly determine the disaccharide composition of heparan sulfate by enzymatic depolymerisation and SAX-HPLC analysis. A complementary method for identification and characterisation of heparan sulfate can be found at Carnachan and Hinkley (2017) .
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[Background] A number of methods exist for the structural analysis of heparin and HS. This protocol aims to provide an optimised methodology for the enzymatic depolymerisation of heparin and HS and the analysis and quantification of the disaccharides produced therein. Very few published analyses consider all aspects of the gross composition including the extent of depolymerisation in conjunction with the disaccharide composition obtained (Skidmore et al., 2006 and 2010; Carnachan et al., 2016) . This is particularly worrisome when the sample is subsequently utilised in a biological assay that is invariably dose-dependent. The enzymatic procedure described herein is the culmination of a detailed study investigating the conditions necessary for optimal enzyme activity and HS depolymerisation (Carnachan et al., 2016) . This procedure is intended to provide a stepwise protocol suitable for a laboratory inexperienced in glycosaminoglycan (GAG) analysis. 3 the supplier's specification. However, when the enzyme activities were assayed using Celsus heparan sulfate and the digestion conditions described below, they were found to be 2.8, 5.0 and 13.8 mIU for Heparin lyases (HL) I, II and III, respectively. HL activities should be independently verified prior to starting the depolymerisation procedure.
Materials and Reagents
2. Heparin or HS (1 mg, in duplicate) is dissolved in a microcentrifuge tube (1.5 ml) with the digestion media (470 µl).
3. Sequential enzyme addition is completed.
a. HL I (one 5 µl aliquot) is added and the solution incubated (37 °C, 2 h, inversion at 9 rpm).
b. HL III (5 µl) is added and incubation continued (1 h). c. HL II (5 µl) is added and incubation continued (18 h).
d. All three enzymes (an additional 5 µl of each) are added at the same time and the solution incubated (gentle inversion, 9 rpm) for a further 24 h.
4. Digests are terminated by heating (100 °C, 5 min).
5. Samples are centrifuged (14,000 x g, 10 min) and the supernatant recovered.
6. The supernatants (2 mg/ml) are then accurately diluted with water to give 100 µg/ml solutions, by taking 50 µl of supernatant and adding 950 µl of water. The 100 µg/ml solutions are then filtered (0.22 µm) and analysed.
B. Analysis procedure 1. HPLC is completed using a binary solvent system and a flow rate of 1 ml/min at 40 °C. Following long-term storage and prior to injecting the first sample, the column is conditioned by flushing thoroughly with water, then with 100% B for 10 min before equilibrating the column with the starting conditions (0% B) for 2 min. Digest and standard solutions (see below) are injected by autosampler (50 µl injection volume) and the disaccharides separated using a gradient system, 0% B (1 min), 0% to 35% B (over 31 min), 35% to 65% B (over 15 min), 100% B (10 min). Post analysis column re-equilibration 0% B (3 min).
2. Disaccharides are detected by absorbance at their absorbance maxima of 232 nm.
3. Standard curves for each disaccharide standard are prepared by dissolution of each of the twelve heparin-derived disaccharide standards (supplied as 1.0 mg samples) to give 1 mg/ml stock solutions in water. These stock solutions are in turn used to prepare a twelve disaccharide standard mix containing 20 µg/ml of each standard which was subsequently serially diluted to prepare solutions containing 10, 5, 2.5, 1.25, 0.625 and 0.3125 µg/ml of each disaccharide.
These standard solutions are analysed with each batch of digests (see Figure 1 ). Linear calibration curves (concentration vs peak area) with R 2 values of > 0.998 can be generated.
4. For the enzyme digests, data reported are the average of two digests. Each digest is analysed by HPLC in duplicate (Figure 1) . Disaccharides in the digest can be identified by elution times relative to the twelve heparin-derived disaccharide standards and quantified using the calibration curves.
www.bio-protocol.org/e2197 2. Using the standard curves and integrated areas for each of the disaccharide peaks it is possible to determine the proportion of each disaccharide present in the sample. This data can be used to calculate the normalised proportion of each disaccharide and the total mass of disaccharides produced by the digestion (Table 1) .
3. The compositions reported are the mean from the four HPLC runs; duplicate analysis of the two digests completed on each sample. 
